An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT01741688
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — BIOLOGICAL
    Tocilizumab was administered according to the local label.

Study Details

This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis. Eligible participants initiated on tocilizumab treatment in accordance with the local label were followed for 6 months.

Key Dates

Start date
Oct 26, 2012
Status verified
Jun 2017
Primary completion
Mar 6, 2014
Completion
Mar 6, 2014

Study Design

Enrollment
16 participants (actual)

Arms

  • Arm: Tocilizumab
    Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).

Primary Outcome Measure

Number of Participants on Tocilizumab at 6 Months After Treatment Initiation [ Time Frame: At 6 months ]

Related Studies